Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q2TAA5
UPID:
ALG11_HUMAN
Alternative names:
Asparagine-linked glycosylation protein 11 homolog; Glycolipid 2-alpha-mannosyltransferase
Alternative UPACC:
Q2TAA5; A5PLP3; B4DKW9; Q5TAN9; Q6DKI6; Q96FI7
Background:
GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase, also known as Asparagine-linked glycosylation protein 11 homolog and Glycolipid 2-alpha-mannosyltransferase, plays a pivotal role in glycoprotein biosynthesis. This enzyme is crucial for the synthesis of Man5GlcNAc(2)-PP-dolichol core oligosaccharide, facilitating the addition of mannose residues in the endoplasmic reticulum.
Therapeutic significance:
The enzyme's involvement in Congenital disorder of glycosylation 1P, a condition marked by a broad spectrum of clinical features including nervous system defects and immunodeficiency, underscores its therapeutic potential. Targeting GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase could lead to novel treatments for this congenital disorder.